Pfizers pulmonary arterial hypertension med gets FDA nod
The FDA has approved an intravenous form of sildenafil (Revatio; Pfizer), a phosphodiesterase-5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension in adult patients.
The drug, available in both tablet and intravenous formula, is an injection given to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension patients.
According to New York City-based Pfizer, maintaining medical therapy can demonstrate a delay in clinical worsening for patients. The injection is administered to patients with pulmonary arterial hypertension who are unable to take medication orally.
According to the American College of Chest Physicians, sildenafil is recommended for patients its clinical practice guidelines for the treatment of pulmonary arterial hypertension.
The sildenafil injection will be available in a single-use vial with a recommended dose of 10 mg (12.5 mL) administered three times a day. The drug is also supplied in a 20 mg tablet administered three times per day.
The drug, available in both tablet and intravenous formula, is an injection given to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension patients.
According to New York City-based Pfizer, maintaining medical therapy can demonstrate a delay in clinical worsening for patients. The injection is administered to patients with pulmonary arterial hypertension who are unable to take medication orally.
According to the American College of Chest Physicians, sildenafil is recommended for patients its clinical practice guidelines for the treatment of pulmonary arterial hypertension.
The sildenafil injection will be available in a single-use vial with a recommended dose of 10 mg (12.5 mL) administered three times a day. The drug is also supplied in a 20 mg tablet administered three times per day.